Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free CRBU Stock Alerts

Caribou Biosciences (CRBU) Competitors

Caribou Biosciences logo
$1.54 -0.08 (-4.94%)
As of 03:34 PM Eastern
Compare

CRBU vs. IRWD, RGNX, VALN, SVA, and AUTL

Should you buy Caribou Biosciences stock or one of its competitors? Caribou Biosciences's main competitors and comparable companies include Ironwood Pharmaceuticals (IRWD), REGENXBIO (RGNX), Valneva (VALN), Sinovac Biotech (SVA), and Autolus Therapeutics (AUTL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Caribou Biosciences compare to Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Ironwood Pharmaceuticals has higher revenue and earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ironwood Pharmaceuticals$296.15M2.34$24.02M$0.775.45
Caribou Biosciences$10.04M16.45-$148.12M-$1.08N/A

In the previous week, Ironwood Pharmaceuticals had 8 more articles in the media than Caribou Biosciences. MarketBeat recorded 9 mentions for Ironwood Pharmaceuticals and 1 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.44 beat Ironwood Pharmaceuticals' score of 0.50 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Ironwood Pharmaceuticals Neutral
Caribou Biosciences Positive

Ironwood Pharmaceuticals presently has a consensus price target of $6.23, suggesting a potential upside of 48.41%. Caribou Biosciences has a consensus price target of $7.75, suggesting a potential upside of 403.25%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Ironwood Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ironwood Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.57
Caribou Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Caribou Biosciences' net margin of -1,030.42%. Ironwood Pharmaceuticals' return on equity of -58.38% beat Caribou Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ironwood Pharmaceuticals33.36% -58.38% 34.93%
Caribou Biosciences -1,030.42%-89.11%-62.47%

77.5% of Caribou Biosciences shares are held by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are held by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ironwood Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market.

Summary

Ironwood Pharmaceuticals beats Caribou Biosciences on 9 of the 16 factors compared between the two stocks.

How does Caribou Biosciences compare to REGENXBIO?

REGENXBIO (NASDAQ:RGNX) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

REGENXBIO has a net margin of -112.58% compared to Caribou Biosciences' net margin of -1,030.42%. Caribou Biosciences' return on equity of -89.11% beat REGENXBIO's return on equity.

Company Net Margins Return on Equity Return on Assets
REGENXBIO-112.58% -220.07% -46.04%
Caribou Biosciences -1,030.42%-89.11%-62.47%

In the previous week, REGENXBIO had 21 more articles in the media than Caribou Biosciences. MarketBeat recorded 22 mentions for REGENXBIO and 1 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.44 beat REGENXBIO's score of 0.18 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
REGENXBIO Neutral
Caribou Biosciences Positive

REGENXBIO has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.38, indicating that its stock price is 138% more volatile than the broader market.

Caribou Biosciences has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
REGENXBIO$170.44M3.66-$193.88M-$3.79N/A
Caribou Biosciences$10.04M16.45-$148.12M-$1.08N/A

REGENXBIO presently has a consensus price target of $23.27, indicating a potential upside of 146.27%. Caribou Biosciences has a consensus price target of $7.75, indicating a potential upside of 403.25%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than REGENXBIO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
REGENXBIO
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.62
Caribou Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Caribou Biosciences beats REGENXBIO on 10 of the 17 factors compared between the two stocks.

How does Caribou Biosciences compare to Valneva?

Valneva (NASDAQ:VALN) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Valneva has a net margin of -110.33% compared to Caribou Biosciences' net margin of -1,030.42%. Caribou Biosciences' return on equity of -89.11% beat Valneva's return on equity.

Company Net Margins Return on Equity Return on Assets
Valneva-110.33% -153.20% -39.50%
Caribou Biosciences -1,030.42%-89.11%-62.47%

Valneva has higher revenue and earnings than Caribou Biosciences. Valneva is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Valneva$197.56M3.05-$130.33M-$2.11N/A
Caribou Biosciences$10.04M16.45-$148.12M-$1.08N/A

Valneva has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market.

11.4% of Valneva shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valneva presently has a consensus target price of $9.30, suggesting a potential upside of 46.46%. Caribou Biosciences has a consensus target price of $7.75, suggesting a potential upside of 403.25%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Valneva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Valneva
2 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
Caribou Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

In the previous week, Valneva had 3 more articles in the media than Caribou Biosciences. MarketBeat recorded 4 mentions for Valneva and 1 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.44 beat Valneva's score of 0.29 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Valneva Neutral
Caribou Biosciences Positive

Summary

Caribou Biosciences beats Valneva on 11 of the 17 factors compared between the two stocks.

How does Caribou Biosciences compare to Sinovac Biotech?

Caribou Biosciences (NASDAQ:CRBU) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Sinovac Biotech has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,030.42%. Sinovac Biotech's return on equity of 0.00% beat Caribou Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Caribou Biosciences-1,030.42% -89.11% -62.47%
Sinovac Biotech N/A N/A N/A

Sinovac Biotech has higher revenue and earnings than Caribou Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caribou Biosciences$10.04M16.45-$148.12M-$1.08N/A
Sinovac Biotech$386.01M1.67-$59.68MN/AN/A

77.5% of Caribou Biosciences shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Caribou Biosciences currently has a consensus price target of $7.75, indicating a potential upside of 403.25%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Caribou Biosciences is more favorable than Sinovac Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caribou Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Caribou Biosciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

In the previous week, Caribou Biosciences and Caribou Biosciences both had 1 articles in the media. Sinovac Biotech's average media sentiment score of 1.89 beat Caribou Biosciences' score of 1.44 indicating that Sinovac Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Caribou Biosciences Positive
Sinovac Biotech Very Positive

Summary

Caribou Biosciences and Sinovac Biotech tied by winning 7 of the 14 factors compared between the two stocks.

How does Caribou Biosciences compare to Autolus Therapeutics?

Caribou Biosciences (NASDAQ:CRBU) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Caribou Biosciences has higher earnings, but lower revenue than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caribou Biosciences$10.04M16.45-$148.12M-$1.08N/A
Autolus Therapeutics$75.39M8.33-$287.53M-$1.06N/A

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Autolus Therapeutics has a net margin of -238.66% compared to Caribou Biosciences' net margin of -1,030.42%. Caribou Biosciences' return on equity of -89.11% beat Autolus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Caribou Biosciences-1,030.42% -89.11% -62.47%
Autolus Therapeutics -238.66%-178.66%-49.34%

In the previous week, Autolus Therapeutics had 2 more articles in the media than Caribou Biosciences. MarketBeat recorded 3 mentions for Autolus Therapeutics and 1 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.44 beat Autolus Therapeutics' score of 0.96 indicating that Caribou Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Caribou Biosciences Positive
Autolus Therapeutics Positive

Caribou Biosciences presently has a consensus target price of $7.75, indicating a potential upside of 403.25%. Autolus Therapeutics has a consensus target price of $10.00, indicating a potential upside of 323.73%. Given Caribou Biosciences' higher probable upside, research analysts clearly believe Caribou Biosciences is more favorable than Autolus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caribou Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Autolus Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.88

Caribou Biosciences has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.07, indicating that its share price is 107% more volatile than the broader market.

Summary

Autolus Therapeutics beats Caribou Biosciences on 9 of the 17 factors compared between the two stocks.

Get Caribou Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRBU vs. The Competition

Export
MetricCaribou BiosciencesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$165.10M$3.91B$7.11B$12.80B
Dividend YieldN/A3.61%2.54%11.27%
P/E Ratio-1.4311.79272.8425.46
Price / Sales16.451,392.91685.44122.44
Price / CashN/A44.0628.7436.03
Price / Book1.1816.7311.016.31
Net Income-$148.12M-$22.71M$3.47B$349.45M
7 Day Performance-6.10%2.32%1.03%-0.23%
1 Month Performance5.48%12.44%8.03%4.24%
1 Year Performance-17.65%53.96%23.84%14.60%

Caribou Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRBU
Caribou Biosciences
1.9798 of 5 stars		$1.54
-4.9%		$7.75
+403.2%		-13.4%$165.10M$10.04MN/A100
IRWD
Ironwood Pharmaceuticals
2.8 of 5 stars		$4.13
-3.7%		$6.23
+50.9%		+212.9%$708.88M$296.15M5.36220
RGNX
REGENXBIO
2.9822 of 5 stars		$8.06
-24.8%		$23.45
+191.0%		+8.2%$707.66M$170.44MN/A370
VALN
Valneva
2.0656 of 5 stars		$6.75
-3.0%		$9.30
+37.8%		-27.3%$660.40M$197.56MN/A700
SVA
Sinovac Biotech
1.1215 of 5 stars		$6.47
flat		N/AN/A$644.66M$386.01MN/A3,008

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CRBU) was last updated on 8/31/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel